25 January 2016
NEW YORK (GenomeWeb) – Epic Sciences has announced it will use Station X's GenePool platform as part of data analysis for its collaborations with pharmaceutical companies to develop circulating tumor cell-based companion diagnostics.
GenePool is a web-based software service that allows researchers to analyze and share data. The software is pre-loaded with standard clinical reporting capabilities for incidental findings and tumor profiling, but is also customizable, Station X said in a statement.
"Station X delivers a sophisticated data management and collaboration platform that is allowing us to deliver on our strategy to develop a robust commercial platform with a strong and diverse pipeline of diagnostic and companion diagnostic products," Mark Landers, Director of Genomics at Epic Sciences, said in a statement. The firm noted it is developing companion diagnostics in partnership with pharmaceutical companies in more than 50 active clinical trials.
The deal comes as San Francisco-based Station X begins to align itself with firms offering liquid biopsy technology and services. Last month, the firm announced a partnership with Circulogene.
For Epic Sciences, the announcement comes on the heels of a partnership with the University of Pennsylvania to find biomarkers using CTC technology, announced in November 2015, and CAP accreditation for its San Diego laboratory earlier this month.
PrintMerry Christmas and Happy New Year!
28 December 2024
NovaMedica team in the TOP 100 INFLUENTIAL PEOPLE IN THE PHARMACEUTICAL BUSINESS 2024
28 November 2024
05 November 2024
New guidance to aid cost-effectiveness analysis of new drugs
20 January 2025
The Ministry of Health may expand its patent use powers
20 January 2025
Gene therapy gel for epidermolysis bullosa is now used in Russia
20 January 2025
In 2024, salaries of Russian medical workers in the ambulance service increased by 12-14%
17 January 2025